Product Description
Mechanisms of Action: PAC1 Agonist
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Universitaire Ziekenhuizen KU Leuven
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02355756 |
CCP14-3301-PAC1 | P1 |
Completed |
Healthy Volunteers |
2015-04-01 |
2022-09-27 |
Primary Endpoints |